Main Article Content
Objectives: Long-term survival is an important endpoint in management of different malignancies which is rarely assessed due to unfeasibility of follow-up for long duration of time. In this study, we explored real-world data on cancer’s long-term survival using historical records from the Surveillance, Epidemiology, and End Results (SEER) Program. Besides reporting the 5-year relative survival, we analyzed the 10- and 20- year survival rates for different types of cancers. Additionally, survival trends as a function of time, age, and tumor type were reviewed and reported. Methods: We used SEER*Stat (version 188.8.131.52) for data acquisition from the SEER 9 Regs (Nov 2019 Submission) database. Data of patients diagnosed with cancer between 1975 and 2014 were retrieved and included in the analysis. Results: For patients diagnosed with any malignant disease (n = 4,412,024), there was a significant increase in median overall survival over time (p<0.001). The 20-, 10-, and 5-year survival rates were higher in solid tumors compared to hematological malignancies (50.8% vs. 38%, 57% vs. 47.4%, and 62.2% vs. 57.4%, respectively). The highest 20-year relative survival rates were observed in thyroid cancer (95.2%), germ cell and trophoblastic neoplasms (90.3%), melanoma (86.8%), Wilms’ tumor (86.2%), and prostate cancer (83.5%). Conclusions: Long-term follow-up data were suggestive of high 20-year relative survival rates for most tumor types. Relative survival showed an improving trend over time especially in solid tumors.
Keywords: Survival; Neoplasms; SEER Program; Prognosis; United States.
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.